Susan E. Lacy - Shrewsbury MA, Emma Fung - Shrewsbury MA, Jonathan P. Belk - Sterling MA, Richard W. Dixon - Jefferson MA, Michael Roguska - Ashland MA, Paul R. Hinton - Sunnyvale CA, Shankar Kumar - Pleasanton CA,
Assignee:
Abbott Laboratories - Abbott Park IL
International Classification:
C07K 16/00
US Classification:
5303871, 4241301
Abstract:
The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e. g. , in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.
Chengbin Wu - Shrewsbury MA, Richard W. Dixon - Jefferson MA, Jonathan P. Belk - Sterling MA, Maria A. Argiriadi - Wayland MA, Hua Ying - Holden MA, Carolyn A. Cuff - Grafton MA, Terry L. Melim - Derry NH, Shankar Kumar - Pleasanton CA, Paul R. Hinton - Sunnyvale CA, Yan Chen - Fremont CA,
Assignee:
Abbott Laboratories - Abbott Park IL
International Classification:
C12P 21/08
US Classification:
5303879, 4241331
Abstract:
The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e. g. , in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
Chengbin Wu - Shrewsbury MA, Richard W. Dixon - Jefferson MA, Jonathan P. Belk - Sterling MA, Maria A. Argiriadi - Wayland MA, Hua Ying - Holden MA, Carolyn A. Cuff - Grafton MA, Terry L. Melim - Derry NH, Shankar Kumar - Pleasanton CA, Paul R. Hinton - Sunnyvale CA, Yan Chen - Fremont CA,
Assignee:
AbbVie Inc. - North Chicago IL
International Classification:
C07H 21/04
US Classification:
536 2353, 435325
Abstract:
The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e. g. , in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
Susan E. Lacy - Shrewsbury MA, Emma Fung - Shrewsbury MA, Jonathan P. Belk - Sterling MA, Richard W. Dixon - Jefferson MA, Michael Roguska - Ashland MA, Paul R. Hinton - Sunnyvale CA, Shankar Kumar - Pleasanton CA,
Assignee:
Abbvie Inc. - North Chicago IL
International Classification:
C07H 21/04
US Classification:
536 2353, 5303871, 435326
Abstract:
The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e. g. , in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.
Antibodies To Erythropoietin Receptor And Uses Thereof
Edward Reilly - Libertyville IL, Susan Lacy - Shrewsbury MA, Emma Fung - Shrewsbury MA, Jonathan Belk - Sterling MA, Michael Roguska - Ashland MA,
International Classification:
C07K016/28 C12Q001/70 G01N033/53
US Classification:
435007100, 530388220
Abstract:
The present invention relates to antibodies and antigen-binding portions thereof that bind to and activate an erythropoietin receptor. The invention also relates to nucleic acid sequences encoding such antibodies and antigen-binding portions. The present invention further relates to methods of activating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies and antigen-binding portions, methods of treatment, as well as pharmaceutical compositions comprising said antibodies and antigen-binding portions.
Antibodies To Erythropoietin Receptor And Uses Thereof
Edward Reilly - Libertyville IL, Susan Lacy - Shrewsbury MA, Emma Fung - Shrewsbury MA, Jonathan Belk - Sterling MA, Michael Roguska - Ashland MA,
International Classification:
A61K 39/395 C07K 16/28
US Classification:
424143100, 530388220
Abstract:
The present invention relates to antibodies and antigen-binding portions thereof that bind to and activate an erythropoietin receptor. The invention also relates to nucleic acid sequences encoding such antibodies and antigen-binding portions. The present invention further relates to methods of activating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies and antigen-binding portions, methods of treatment, as well as pharmaceutical compositions comprising said antibodies and antigen-binding portions.
Antibodies To Erythropoietin Receptor And Uses Thereof
Edward Reilly - Libertyville IL, Susan Lacy - Shrewsbury MA, Emma Fung - Shrewsbury MA, Jonathan Belk - Sterling MA, Michael Roguska - Ashland MA, Vincent Stoll - Libertyville IL, Clarissa Jakob - Grayslake IL,
The present invention relates to antibodies and antigen-binding portions thereof that bind to and activate an erythropoietin receptor. The invention also relates to nucleic acid sequences encoding such antibodies and antigen-binding portions. The present invention further relates to methods of activating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies and antigen-binding portions, methods of treatment, as well as pharmaceutical compositions comprising said antibodies and antigen-binding portions. The invention further provides compositions and crystals of an erythropoietin receptor in complex with an anti-erythropoietin receptor antibody. Specifically, the high-resolution structure provides binding sites defined by the structure coordinated determined herein.
Chung-ming Hsieh - Newton MA, Jonathan P. Belk - Grantham NH, Jennifer M. Perez - Worcester MA, Lorenzo Benatuil - Medford MA,
International Classification:
C40B 50/06 C12N 1/19
US Classification:
506 26, 4352542
Abstract:
This invention is directed to the transformation of yeast, and mutants thereof, by electroporation, which result in stably transformed yeast host cells that express recombinant products. This invention also is directed to transformed yeast cells and libraries.